Sanofi rids itself of Zimulti suit, but its legacy weighs on new-generation obesity pills

Eric Palmer When the FDA approved two new obesity drugs last year, there was some surprise because of the ugly regulatory and legal entanglements of weight-loss drugs that preceded ...

GSK gets double dose of good news for Breo Ellipta

Eric Palmer GlaxoSmithKline got a double dose of good news today about its respiratory drug Breo Ellipta, known as Relvar Ellipta in other markets. Regulators in Europe recommended ...

Seven Health Systems Form Interstate Alliance

barbara.lempert Seven of the Nation’s Most Recognized Health Systems Form Interstate Alliance AllSpire Health Partners to create foundational changes in health care quality and healthier ...

UPDATED: San Diego biotech insider accused of shooting RNAi expert and brother-in-law

Ryan McBride San Diego police say that biotech entrepreneur Hans Petersen shot and wounded his brother-in-law Ron Fletcher and the University of California, San Diego scientist Steven ...

Langer’s Bind Therapeutics raises $70.5M in IPO

Emily Mullin Yet another biotech has joined the raging IPO craze. Nanomedicine company Bind Therapeutics has raised $ 70.5 million in a public offering of its stock priced at $ 15 ...

India court allows J&J to resume production at plant ordered closed 3 months ago

Eric Palmer Johnson & Johnson, which has been battling a host of problems tied to its consumer healthcare operations, is back in the baby powder business in Mumbai, India. A plant ...

Californians With Medicaid Coverage Have Highest Increase in Emergency Department Visits

barbara.lempert Among Adults in California, Those With Medicaid Coverage Have Highest Increase in Emergency Department Visits “Emergency department (ED) use has been affected by ...

New guidance issued by US Labor Department on same-sex marriages and employee benefit plans

barbara.lempert WASHINGTON, Sept. 18, 2013 — The U.S. Department of Labor today announced new guidance interpreting the Supreme Court’s decision in United States v. Windsor. ...

Merck’s Perlmutter shares plans for R&D reboot, likes and dislikes

Ryan McBride Perlmutter has granted a few interviews this month with journalists and analysts, providing some clarity on how the immunologist plans to reshape how Merck prioritizes ...

Roche’s new star Kadcyla picks up EU nod

Eric Palmer Roche's cancer drug Kadcyla, an expected superstar that is pegged to assume the mantle of Herceptin in later years, has moved forward in Europe where Friday it was recommended ...

Blink Of An Eye: Chosterol-Lowering Drugs Linked To Cataracts

esilverman Can statins cause cataracts? Over the years, there has been confusion owing to mixed results from different studies. Yet another study, however, finds that such ...

M&A buzz: ViroPharma could go for $60 per share in buyout

Ryan McBride The rare-disease drug specialist ViroPharma has been generating buyout buzz all week after reports that the company brought on the services of Goldman Sachs to hunt for ...
Page 10 of 24« First...89101112...20...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS